Table 2

Prevalence of therapeutic duplication and regression analyses for risk of duplication

FC
(n=151 632)
FDC
(n=307 833)
Therapeutic duplication, n (%)918 (0.61)2723 (0.88)
 ARB57 (0.04)404 (0.13)
 ACE inhibitor103 (0.07)201 (0.07)
 Beta blocker129 (0.09)128 (0.04)
 Calcium channel blocker629 (0.41)2014 (0.65)